Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Advancing Treatment Strategies and Real-World Perspectives for mCRC and GI Neuroendocrine Neoplasms; With Rocío García-Carbonero, MD, PhD

August 12th 2025

Rocío García-Carbonero, MD, PhD, discusses trends in colorectal cancer and other gastrointestinal malignancies, presented at the 2025 ESMO GI Cancers Congress.

Dr Pal on the Predictive Utility of KIM-1 Expression in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

How Chemoimmunotherapy, PRRT, and First-Line Immunotherapy Are Reshaping GI Cancer Management

August 12th 2025

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

Daratumumab Delays Clinical Progression, Provides Proof-of-Concept for Early Intervention in MRD-Relapsed Multiple Myeloma

August 12th 2025

Krzysztof Jamroziak, MD, PhD, discusses the feasibility of MRD-guided, early intervention with daratumumab in patients with multiple myeloma.

Dr Gershon on Ongoing Research Priorities for NF1-Associated Plexiform Neurofibromas

August 11th 2025

Timothy R. Gershon, MD, PhD, discusses ongoing research priorities neurofibromatosis type 1–associated plexiform neurofibromas

Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer

August 11th 2025

Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.

Ongoing Research Prompts Key Sequencing Considerations in CRC, Pancreatic Cancer

August 11th 2025

Tanios S. Bekaii-Saab, MD, discusses sequencing approaches in metastatic pancreatic cancer and colorectal cancer.

Imsapepimut and Etimupepimut Plus Pembrolizumab Shows Clinical Improvement in PFS for Advanced Melanoma

August 11th 2025

The off-the-shelf therapeutic cancer vaccine plus pembrolizumab improved PFS vs pembrolizumab alone in advanced melanoma.

FDA Approves Oncomine Dx Target Test as Zongertinib Companion Diagnostic in Nonsquamous NSCLC With HER2 TKD Mutations

August 11th 2025

The FDA has approved the Oncomine Dx Target Test as a companion diagnostic for zongertinib in NSCLC harboring HER2 TKD mutations.

LV20.19 CAR T-Cell Therapy Yields 100% ORR in R/R Mantle Cell Lymphoma

August 11th 2025

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

SAR446523 Receives FDA Orphan Drug Designation for R/R Myeloma

August 9th 2025

The FDA granted orphan drug designation to SAR446523 for relapsed/refractory multiple myeloma.

Dr Florez on Emerging Strategies to Address Checkpoint Inhibitor Resistance in NSCLC

August 8th 2025

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

HER2-Targeted Therapies and Chemoimmunotherapy Continue to Advance Biliary Tract Cancer Management

August 8th 2025

Tanios S. Bekaii-Saab, MD, highlights how HER2-directed agents, chemoimmunotherapy, and biomarker-driven strategies are expanding options for biliary tract cancers.

Dr Florez on the Role of First-Line IO for BRAF V600E+ Metastatic NSCLC

August 8th 2025

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Dr Kremyanskaya on the Efficacy of Divesiran in Polycythemia Vera

August 8th 2025

Marina Kremyanskaya, MD, PhD, discusses safety and early efficacy findings with divesiran in polycythemia vera.

Dr Dietrich on the FDA Approval of Zongertinib for HER2 TKD–Mutated Nonsquamous NSCLC

August 8th 2025

Martin Dietrich, MD, PhD, discusses the FDA accelerated approval of zongertinib for HER2-mutated or metastatic nonsquamous NSCLC.

Dr Sanborn on Early Efficacy and Safety Data With Sigvotatug Vedotin Plus Pembrolizumab in NSCLC

August 8th 2025

Rachel E. Sanborn, MD, discusses preclinical and early clinical data supporting the use of the IB6-directed ADC sigvotatug vedotin in patients with NSCLC.

Dr Florez on the Role of Chemoimmunotherapy in Borderline Resectable NSCLC

August 8th 2025

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Chromophobe RCC Microenvironment Study Shows Determinants of Impaired Antitumor Immunity

August 8th 2025

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Dr Florez on First-Line Treatment Factors in EGFR+ NSCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.